Terms ending in 2030
Every in-force patent on ZymoGenetics Inc.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,005,837 | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS In force · Medium confidence | Zymogenetics, Inc. | In force | Medium confidence | |
| US 8,071,090 | Stabilized Thrombin Compositions In force · High confidence | Baxter International, Inc. | In force | High confidence | |
| US 10,570,187 | Soluble Hybrid Fcgamma Receptors and Related Methods In force · High confidence | ZymoGenetics, Inc. | In force | High confidence | |
| US 8,470,979 | Humanized Antibody Molecules Specific for IL-31 In force · High confidence | ZymoGenetics, Inc. | In force | High confidence | |
| US 9,663,566 | Soluble Hybrid Fcgamma Receptors and Related Methods In force · High confidence | ZymoGenetics, Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by ZymoGenetics Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.